Diabetes · Phase 3
TRANSCEND-T2D-1: retatrutide in early diabetes
What was tested?
Retatrutide versus placebo in adults with type 2 diabetes managed with diet and exercise. ↗
Registered primary question: Change in HbA1c from baseline to week 40. ↗
What the reviewed report found
Journal year 2026 · Article summary reviewed 2026-09-15
Under the treatment-regimen analysis, HbA1c decreased by 1.69–1.94 percentage points across active groups versus 0.81 with placebo. Gastrointestinal events were common; adverse-event discontinuations occurred in 2–5% of active groups and none of the placebo group.↗
Keep in context: The trial randomized 537 of 930 screened participants. Weight change was secondary to the primary glycemic endpoint; this 40-week study does not establish long-term cardiovascular outcomes. ↗↗
Participants, design, limitations and sources
Registry snapshot
- Registry enrollment
- 537 · reported actual
- Registry status
- Completed
- Allocation and masking
- Randomized · Double
- Design
- Parallel
- Eligible ages
- 18 Years; maximum not specified
- Registry results
- Not posted in this snapshot
Registry source ↗ · Updated 2026-03-05; retrieved 2026-09-20. Registry enrollment is not necessarily the analyzed sample in a publication. Posted registry results and published article results are separate.
TRANSCEND-T2D-1: phase 3 diabetes study
- Design in the report
- A blinded randomized placebo-controlled trial assessed 40-week glycated hemoglobin change under NCT06354660.↗
- Participants in the report
- The trial randomized 537 adults with type 2 diabetes inadequately controlled with diet and exercise alone.↗
- Limitations
- HbA1c and weight changes do not establish prevention of long-term complications. The report recorded two deaths in one active group, which the authors considered unrelated to study treatment; it reported no severe hypoglycemia.↗
This reading covers the article abstract and record metadata. Read its preserved Human Evidence Review →
How the study identity and sources were checked
Study context checked 2026-09-20. Existing article summaries keep their original review dates. This is a selected study reading, not a complete literature or full-text appraisal.
Registry
Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1) ↗
Protocol identifier: 18804. Sponsor: Eli Lilly and Company.
Retrieved 2026-09-20; SHA-256 978eee24dd651a880bc81ae176e61e996bb9c6745b4081587b9576e5ab18d905.
PMID 42250575
Exact trial identity is declared in PubMed’s ClinicalTrials.gov databank field. The registry independently labels this reference DERIVED. These source labels do not establish that every result in a paper applies to this trial.
Identity metadata retrieved 2026-09-20. EFetch batch XML; locate MedlineCitation/PMID 42250575. SHA-256 adc8edd8b150d99a3641ddbc74c59db6916cf35d9d6246838aaff2cc195ae1cb.
Scientific summary uses the original 2026-09-15 source snapshot: SHA-256 c7b0d7e8d9f2053a0083809311fa312b449f6271b7cde41ea747e8bdf0a318c4.